MorphoSys has moved to add targets for its immuno-oncology arsenal. The agreement sees MorphoSys gain access to tumor-associated peptides discovered by its compatriot Immatics Biotechnologies in exchange for some of its antibodies, with both companies paying out milestones as their respective programs advance.
Thanks to pharma's R&D cost-cutting efforts, the CRO industry will expand at nearly a 10% clip through 2019, a new report says, citing trends that many industry-watchers will find familiar.
ReShape Medical is digesting $38 million in Series D financing as it seeks to commercialize its just-approved weight-loss balloon, which gives the obese a minimally invasive option that avoids the nasty side effects of surgeries like malnutrition following duodenal switch surgery, which involves removal of most of the stomach.
Mark Mamula, a professor of medicine at Yale University, created a cancer vaccine that's designed to prompt the body's immune system to attack tumors. It worked great in mice, but he wanted to see how it would perform in a more realistic model of human cancer, so now he has teamed up with the Veterinary Cancer Center in Norwalk, CT, to test the vaccine in dogs. Mamula hopes the insights from the dog trial will lead to a human trial in a year or so.
Boston's Veritas Genetics received a CE mark to conduct BRCA gene testing for likelihood of inheriting breast and inheriting cancer in Europe.
Palo-Alto, CA-based MocaCare has raised $2 million to launch a tiny handheld monitor that purports to evaluate cardiovascular health. The startup is aiming for a September launch of its device, MocaHeart, with its accompanying smartphone app with a price point of $149.99.
Harpreet Singh, the CSO and co-founder of Germany's Immatics Biotechnologies, has been splitting his time between Germany and Houston in order to set up a new biotech company that will collaborate with some top researchers at MD Anderson on overcoming some of the limitations to the adoptive T cell therapies now in the immuno-oncology pipeline.
When George Yancopoulos walked away from Columbia University to join Regeneron in 1989, the decision to leave academia for industry was at least partly motivated by the pay differential. The move paid off and then some, with Yancopoulos becoming the first billionaire biopharma R&D head at a time when the best-paid research institute chiefs are pulling in just north of $1 million a year.
As med tech companies roll out innovative radiation devices to treat breast cancer, medical experts are debating the pros and cons of a new technique that could be less expensive and more convenient than traditional therapy for the disease.
Dexcom had put a bit of a Band-Aid on its mobile strategy--its prior smart device-compatible continuous glucose monitor required a separate worn transmitter and a dedicated handheld receiver. But now the FDA has approved the first CGM system, dubbed G5, which connects an all-in-one adhesive sensor/transmitter combo directly to an app on a smart device.